Granulomas and inflammation: Host-Directed Therapies for Tuberculosis [PDF]
Frontiers in Immunology, 2016 Tuberculosis remains a leading global health problem that is aggravated by emergence of drug-resistant strains, which account for increasing number of treatment-refractory cases.
Hlumani Ndlovu, Mohlopheni J Marakalala
doaj +8 more sources
Host-directed therapies for tuberculous pericarditis [PDF]
International Journal of Infectious Diseases, 2015 TB Pericarditis is associated with significant inflammatory and immune responses which can paradoxically cause injury to the pericardium and myocardium. Management with anti-TB therapy alone does not prevent complications or reduce mortality.
Alimuddin Zumla +3 more
doaj +4 more sources
Potentials of Host-Directed Therapies in Tuberculosis Management [PDF]
Journal of Clinical Medicine, 2019 Tuberculosis (TB) remains as a leading cause of mortality in developing countries, persisting as a major threat to the global public health. Current treatment involving a long antibiotic regimen brings concern to the topic of patient compliance ...
Kush Shāh +2 more
exaly +6 more sources
Editorial: Host-Directed Therapies for Tuberculosis [PDF]
Frontiers in Cellular and Infection Microbiology, 2021 Diego L. Costa +4 more
doaj +5 more sources
Target Discovery for Host-Directed Antiviral Therapies: Application of Proteomics Approaches [PDF]
mSystems, 2021 Current epidemics, such as AIDS or flu, and the emergence of new threatening pathogens, such as the one causing the current coronavirus disease 2019 (COVID-19) pandemic, represent major global health challenges.
Merve Cakir +3 more
doaj +6 more sources
Host-directed therapies for multidrug resistant tuberculosis [PDF]
International Journal of Mycobacteriology, 2016 Tuberculosis (TB) causes 1.3 million deaths annually. There are 0.5 million cases of multidrug resistant TB (MDR-TB) and the number of cases is rising globally.
Alimuddin Zumla, Markus Maeurer
doaj +5 more sources
Mitigating the Impact of Antibacterial Drug Resistance through Host-Directed Therapies: Current Progress, Outlook, and Challenges [PDF]
mBio, 2018 Increasing incidences of multidrug resistance in pathogenic bacteria threaten our ability to treat and manage bacterial infection. The development and FDA approval of novel antibiotics have slowed over the past decade; therefore, the adoption and ...
Chih-Yuan Chiang +5 more
doaj +3 more sources
Dual human lung models reveal compartment-specific activity of anti-tuberculosis drugs and host-directed therapies [PDF]
Microbiology SpectrumTuberculosis (TB) remains a major global health challenge that requires new therapeutic strategies to improve drug efficacy, shorten treatment duration, prevent drug resistance, and limit Mycobacterium tuberculosis (Mtb) persistence. Here, we established
Caio César Barbosa Bomfim +21 more
doaj +3 more sources
Improving treatment outcomes for MDR-TB — Novel host-directed therapies and personalised medicine of the future [PDF]
International Journal of Infectious Diseases, 2019 Multidrug-resistant TB (MDR-TB) is a major threat to global health security. In 2017, only 50% of patients with MDR-TB who received WHO-recommended treatment were cured.
Martin Rao +7 more
doaj +4 more sources
Host-directed therapies for COVID-19 [PDF]
Current Opinion in Pulmonary Medicine, 2021 Purpose of review: Severe acute respiratory syndrome coronavirus-2-induced hyperinflammation is a major cause of death or end-organ dysfunction in COVID-19 patients. We review adjunct host-directed therapies (HDTs) for COVID-19 management.
Ramalho, R +3 more
core +5 more sources